Hepatitis C Virus Infection, Metabolic Disorders and Non-alcoholic Fatty Liver Disease: A Literature Review

References (48)

1. 1 Global epidemiology of hepatitis C virus infection [DOI]
2. 2 Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral Obesity [DOI]
3. 3 Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon [DOI]
4. 4 Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease * [DOI]
5. 5 Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients [DOI]
6. 6 Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis C [DOI]
7. 7 Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 [DOI]
8. 8 STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? [DOI]
9. 9 Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response [DOI]
10. 10 The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients [DOI]
11. 11 Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol [DOI]
12. 12 Clearance of HCV Improves Insulin Resistance, Beta-Cell Function, and Hepatic Expression of Insulin Receptor Substrate 1 and 2 [DOI]
13. 13 Hepatitis C Virus Infection and Its Clearance Alter Circulating Lipids [DOI]
14. 14 Genotype‐specific mechanisms for hepatic steatosis in chronic hepatitis C infection [DOI]
15. 15 Race, insulin resistance and hepatic steatosis in chronic hepatitis C [DOI]
16. 16 Meta‐analysis: insulin resistance and sustained virological response in hepatitis C [DOI]
17. 17 Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin [DOI]
18. 18 Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis [DOI]
19. 19 Analysis of Histopathological Manifestations of Chronic Hepatitis C Virus Infection With Respect to Virus Genotype [DOI]
20. 20 Host- and disease-specific factors affecting steatosis in chronic hepatitis C [DOI]
21. 21 Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study [DOI]
22. 22 Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C† [DOI]
23. 23 Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis [DOI]
24. 24 Mechanisms and significance of liver steatosis in hepatitis C virus infection [DOI]
25. 25 New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) [DOI]
26. 26 Effect of Significant Histologic Steatosis or Steatohepatitis on Response to Antiviral Therapy in Patients With Chronic Hepatitis C [DOI]
27. 27 Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection [DOI]
28. 28 Review article: chronic hepatitis C – natural history and cofactors [DOI]
29. 29 Insulin Resistance Among Patients With Chronic Hepatitis C: Etiology and Impact on Treatment [DOI]
30. 30 Obesity predisposes to increased drainage following axillary node clearance: a prospective audit.
31. 31 HCV Infection and Metabolic Syndrome: Which Is the Chicken and Which Is the Egg? [DOI]
32. 32 Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients [DOI]
33. 33 Steatosis and intrahepatic hepatitis C virus in chronic hepatitis [DOI]
34. 34 Dynamics of Alanine Aminotransferase During Hepatitis C Virus Treatment [DOI]
35. 35 The metabolic regulator PGC-1α links hepatitis C virus infection to hepatic insulin resistance [DOI]
36. 36 Reversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral Therapy [DOI]
37. 37 Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin [DOI]
38. 38 Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C [DOI]
39. 39 Type 1 Diabetes Mellitus Provoked by Peginterferon .ALPHA.-2b Plus Ribavirin Treatment for Chronic Hepatitis C [DOI]
40. 40 Pegylated interferon plus ribavirin therapy improves pancreatic β‐cell function in chronic hepatitis C patients [DOI]
41. 41 Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy
42. 42 Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV-Coinfected Persons: The AIDS Clinical Trials Group A5178 Study [DOI]
43. 43 Onset of type 1 diabetes mellitus during peginterferon ??-2b plus ribavirin treatment for chronic hepatitis C [DOI]
44. 44 Hepatitis C virus and liver steatosis: Is it the virus? Yes it is, but not always [DOI]
45. 45 Serum Transaminase Elevations during Pegylated Interferon Treatment of Chronic HCV Hepatitis Probably Induced by Polyethylene Glycol [DOI]
46. 46 Inauspicious contribution of hepatitis C virus and diabetes mellitus targeting kidneys: an update.
47. 47 Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? [DOI]
48. 48 Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Seroprevalence of HIV, HBV and HCV among Prisoners in Sokoto, Nigeria — shares topic coverage
• Evaluation of CD4 T Lymphocyte Cell Levels among Hepatitis B, C and E Viruses Negative Individuals in Ibadan, Southwestern Nigeria — shares topic coverage
• Anti-thyroid Antibodies in Patients with HCV Genotype 3a: A Pilot Study — shares topic coverage
• Hepatitis C Virus Infection among Chronic Renal Failure Patients Pre – Dialysis Therapy in Hodiedah City, Yemen — shares topic coverage
• Evaluation of Saliva as an Alternative Specimen to Serum for Diagnosis of Hepatitis C Virus Infection — shares topic coverage